secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001171843-25-005181
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q2 net loss $56.6M ($0.85/share); cash $630.3M; barzolvolimab shows durable complete response at 76 weeks
--------------------------------------------------------------------------------

- Net loss of $56.6M versus $35.8M in Q2 2024; R&D spend rose to $54.2M on barzolvolimab trials.
- Cash and securities $630.3M (down $43M QoQ); company expects runway through 2027.
- Phase 2 CSU barzolvolimab: up to 41% complete response at 76 weeks (7 months off-treatment); 48% no quality-of-life impact.
- Phase 3 CSU program (EMBARQ-CSU1/2) enrolling globally; Phase 2 CIndU and EoE data due in 2H 2025.
- Phase 1 CDX-622 (bispecific SCF/TSLP) in healthy volunteers: Part 1 data expected 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184325005181/0001171843-25-005181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184325005181/f8k_080625.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer